Cancers | Free Full-Text | Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer | HTML
Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma - ScienceDirect
Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system | PLOS ONE
Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma - ScienceDirect
BBN on Twitter: "1/4 Those looking at future potential interested parties in #AVCT need look no further than the group of companies currently working in and around doxorubicin. If phase 1 data comes in positive then it could put a lot of well-known noses out ...
Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma - ScienceDirect
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment - The Lancet Oncology
Approved oncological nanopharmaceuticals and their applications. | Download Scientific Diagram
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come | Pharmacological Reviews
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Myocet – JR Design
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial - Gynecologic Oncology
What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. - Abstract - Europe PMC
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Is Teva late reporting EU clinical trials?
Substituting doxorubicin with nonpegylated liposomal doxorubicin for the treatment of early breast cancer: results of a retrospective study - Document - Gale Academic OneFile
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer - Annals of Oncology
Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification - The Breast
Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
Hardy AIM on Twitter: "#AVCT Firstly, the oncology sector Phase 1 Clinical Trials expected to commence Q3 2020 Focus? Doxorubicin Holds a massive $1bn Market, despite cardiotoxicity Look at the race for a more efficient use of the drug https://t.co ...
Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma - ScienceDirect
Global Doxorubicin Market to Reach $1.3 Billion by 2026
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come | Pharmacological Reviews
Nanomaterials | Free Full-Text | From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions | HTML
